Funding was provided by TOS, OMA, and OAC. Co‐authors from CPG Direct (C.Á.‐O., F.N., A.M.R.‐G., B.H., X.R.S) supported coordination of the guidance development process (methodology, evidence synthesis, project support, and writing) but did not participate in the selection of questions or discussions to determine recommendations. Conflicts of interest were managed per International Committee of Medical Journal Editors (ICMJE) policies and Guidelines International Network recommendations [9]. All participants disclosed financial and nonfinancial interests via ICMJE forms prior to voting on the iEtD platform and participating in the online panel discussions. No panel members, co‐chairs, or evidence synthesis team members reported conflicts precluding participation. Recusal procedures were established; members with significant and direct financial conflicts, including employment or equity ownership related to products under consideration, could discuss evidence but not judge or vote on recommendations. Using this benchmark, no recusals were made. L.A. reports consulting fees from Novo Nordisk, Eli Lilly, Amgen; payment or honoraria from Eli Lilly, OMA, TOS, ASMBS, ACLM; meetings/travel support from OMA, ASMBS, TOS, ACLM; participation on advisory board for Novo Nordisk; leadership or fiduciary role for OMA; stock/stock options from Enara Health; advisor to AMGA Obesity QuIC Program. J.Q.P. reports grants from NIH; consulting fees from Novo Nordisk, Regeneron, Boehringer Ingelheim, Zealand Pharmaceuticals; payment or honoraria from TOS; meetings/travel support from TOS; participation on advisory board for NIH Metformin in Alzheimer Dementia Prevention. K.B. reports consulting fees from Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Currax; payment or honoraria from Vivus, Abbott, Eli Lilly, Currax; participation on advisory board for Novo Nordisk, Boehringer Ingelheim, Vivus; leadership or fiduciary role for OMA, Illinois Obesity Society, PAs in Obesity Medicine; ownership, Gaining Health. M.‐A.C. reports grants or contracts from NIH, Blue Cross Blue Shield of South Carolina Foundation, American College of Diabetology, Novartis, Amgen, Ionis, Kaneka, Cleerly; consulting fees from Astra Zeneca, Enveda, Keros, Rivus, Wave, Zyversa; participation on advisory boards for Biophytis, Eli Lilly, Novo Nordisk; payment or honoraria from TOS, Endocrine Society, Translational Medicine Academy, AACE, Medical Education Resources, MCE Conferences, Continuing Education Company; meetings/travel support from TOS, the Endocrine Society, AACE; participation on data safety monitoring board for Advarra; leadership or fiduciary role with TOS. A.G. reports consulting fees from Epitomee; payment or honoraria from Novo Nordisk, Acella, Currax, Lilly; participation on advisory board for Novo Nordisk, Acella, Currax, Lilly, Boehringer Ingelheim, WW; leadership or fiduciary role with TOS. D.B.H. reports consulting fees from Amgen, Zealand, AstraZeneca, Lilly, Novo Nordisk, Boehringer Ingelheim; payment or honoraria from TOS, OMA, Haymarket CME, Harvard Blackburn Course; meetings/travel support from TOS, OMA, Haymarket CME, Lilly, Novo Nordisk, World Obesity Federation, ADA; participation on advisory board for Novo Nordisk, Lilly, Amgen, AstraZeneca, Zealand; medical writing support from Lilly, Novo Nordisk. M.L. reports participation on advisory boards for Novo Nordisk, Eli Lilly, Boehringer Ingelheim. J.N. reports employment from OAC. C.Á.‐O. reports employment with Epistemonikos, which received remuneration for the methodology work, and payment or honoraria from the School of Dentistry, Clínica Alemana–Universidad del Desarrollo. F.N. reports employment with Epistemonikos, which received remuneration for the methodology work. A.M.R.‐G. reports employment with Epistemonikos, which received remuneration for the methodology work. B.H. reports consulting fees from TOS, OMA related to the guidance statement; consulting fees from European Association for the Study of Obesity, European Council for People Living with Obesity, Sociedad Mexicana de Nutrición y Endocrinología, Obesity Canada, International Federation for the Surgery of Obesity; meetings/travel support from Bias 180, European Association for the Study of Obesity; leadership or fiduciary role with Bias180, Replica Communications. X.R.S. reports consulting fees from TOS, OMA related to the guidance statement; research grant from SSHRC; consulting fees from Health Services Executive Ireland, European Association for the Study of Obesity, European Council for People Living with Obesity, Sociedad Mexicana de Nutrición y Endocrinología, Fundació Privada Món Clínic Barcelona, Milieu Consulting SRL; speaker honoraria from Blood Pressure Doctor (Sweden), Canadian Cardiovascular Society, Consorci de Salut de Catalunya (Spain), Hospital Clinic Barcelona (Spain), Novo Nordisk Portugal, Eli Lilly Sweden; meetings/travel support from Chilean Society for Clinical Nutrition, Obesity & Metabolism, Spanish Society of Bariatric Surgery, International Federation for the Surgery of Obesity, European Association for the Study of Obesity (Ireland), GB Obesitas (Sweden), Bias 180 (Canada), European Coalition for People Living with Obesity (Ireland), Clínica de obesidad y trastornos de la conducta alimentaria (Mexico), International Federation for the Surgery of Obesity and Metabolic Disorders; leadership or fiduciary role with Bias 180, Replica Communications.
PubMed
